Foghorn Therapeutics (FHTX) Tax Provisions (2023)

Foghorn Therapeutics (FHTX) recorded quarterly Tax Provisions of $2.0 million in Q4 2023, up 169.11% quarter-over-quarter from $738000.0 in Q3 2023.

Foghorn Therapeutics (FHTX) Tax Provisions (2023) Analysis & Trends

Foghorn Therapeutics' Tax Provisions history runs 1 years deep, the most recent figure standing at $2.0 million for Q4 2023.

In Q4 2023, Tax Provisions changed N/A year-over-year to $2.0 million; the TTM figure through Sep 2024 stood at $2.0 million (down 11.34% YoY), while the FY2023 annual figure was $4.2 million, changed N/A from the prior year.
Tax Provisions was $2.0 million for Q4 2023 at Foghorn Therapeutics, up from $738000.0 in the prior quarter.
In the past five years, Tax Provisions ranged from a high of $2.0 million in Q4 2023 to a low of $560000.0 in Q1 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-11.20 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	216,000.00
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-859,000.00
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	221.50 Mn
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Foghorn Therapeutics	282.33 Mn	193.42 Mn	-	-

Download Data